Compare MIST & RPID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MIST | RPID |
|---|---|---|
| Founded | 2003 | 2006 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 163.2M | 178.6M |
| IPO Year | N/A | 2021 |
| Metric | MIST | RPID |
|---|---|---|
| Price | $2.27 | $3.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $6.33 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 5.3M | 104.8K |
| Earning Date | 11-12-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $30,523,000.00 |
| Revenue This Year | N/A | $19.36 |
| Revenue Next Year | N/A | $21.48 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 16.63 |
| 52 Week Low | $0.63 | $0.87 |
| 52 Week High | $3.06 | $4.50 |
| Indicator | MIST | RPID |
|---|---|---|
| Relative Strength Index (RSI) | 44.17 | 41.66 |
| Support Level | $1.61 | $3.27 |
| Resistance Level | $3.06 | $4.07 |
| Average True Range (ATR) | 0.32 | 0.22 |
| MACD | -0.05 | -0.10 |
| Stochastic Oscillator | 44.02 | 26.85 |
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.